Immunogenicity in humans of an edible vaccine for hepatitis B.
A double-blind placebo-controlled clinical trial evaluated the immunogenicity of hepatitis B surface antigen (HBsAg) expressed in potatoes and delivered orally to previously vaccinated individuals. The potatoes accumulated HBsAg at approximately 8.5 microg/g of potato tuber, and doses of 100 g of tuber were administered by ingestion. The correlate of protection for hepatitis B virus, a nonenteric pathogen, is blood serum antibody titers against HBsAg. After volunteers ate uncooked potatoes, serum anti-HBsAg titers increased in 10 of 16 volunteers (62.5%) who ate three doses of potatoes; in 9 of 17 volunteers (52.9%) who ate two doses of transgenic potatoes; and in none of the volunteers who ate nontransgenic potatoes. These results were achieved without the coadministration of a mucosal adjuvant or the need for buffering stomach pH. We conclude that a plant-derived orally delivered vaccine for prevention of hepatitis B virus should be considered as a viable component of a global immunization program.
Thanavala
Yasmin
Y
Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Mahoney
Martin
M
Pal
Sribani
S
Scott
Adrienne
A
Richter
Liz
L
Natarajan
Nachimuthu
N
Goodwin
Patti
P
Arntzen
Charles J
CJ
Mason
Hugh S
HS
D000284:Administration, Oral; D004311:Double-Blind Method; D006510:Hepatitis B Antibodies / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000008:administration & dosage*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage*; D006801:Humans; D030821:Plants, Genetically Modified
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines
N Engl J Med. 1997 Jun 26;336(26):1855-9
9197213
Vaccine. 1997 Mar;15(4):353-6
9141204
Proc Natl Acad Sci U S A. 1996 May 28;93(11):5335-40
8643575
Vaccine. 1995;13 Suppl 1:S47-9
7571830
Science. 1995 May 5;268(5211):714-6
7732379
Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3358-61
7724566
Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11745-9
1465391
Vaccine. 1992;10(10):673-6
1523878
JAMA. 1985 Dec 13;254(22):3187-9
2933532
Lancet. 1984 Aug 25;2(8400):458
6147519
N Engl J Med. 1984 Aug 23;311(8):496-501
6235453
Vaccine. 2004 Oct 22;22(31-32):4385-9
15474732
Vaccine. 2003 Sep 8;21(25-26):4011-21
12922138
J Infect Dis. 2000 Jul;182(1):302-5
10882612
Nat Biotechnol. 2000 Nov;18(11):1167-71
11062435
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11539-44
11553782
Science. 1999 Dec 24;286(5449):2453-4
10636808
Arch Intern Med. 1999 Jul 12;159(13):1481-3
10399900
Am J Public Health. 1999 Jan;89(1):14-8
9987458
Vaccine. 1998 Nov;16 Suppl:S65-8
9915041
J Infect Dis. 1998 Oct;178(4):954-9
9806021
Vaccine. 1998 Aug;16(13):1336-43
9682399
Nat Med. 1998 May;4(5):607-9
9585236
Nat Med. 1998 May;4(5 Suppl):480-4
9585190